Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Context TherapeuticsSTU:6K9 +1.90%36 9-Day RSI is 43.87 as of Aug. 05, 2026. GuruFocus rates STU:6K9 with a GF Score™ of 36/100. The stock has 1 warning sign investors should review. Among 1,420 Biotechnology companies, Context Therapeutics ranks better than 61.69% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Context Therapeutics 9-Day RSI Related Terms
STU:6K9 vs INKT, XLO, BOLD: 9-Day RSI Comparison
For the Biotechnology subindustry, Context Therapeutics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Context Therapeutics 9-Day RSI vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Context Therapeutics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Context Therapeutics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Context Therapeutics (STU:6K9) has a 9-Day RSI of 43.87 as of Aug. 05, 2026. According to the industry distribution chart, Context Therapeutics ranks #544 out of 1420 companies in the Biotechnology industry, placing it in the top 38.3%.
Is Context Therapeutics' 9-Day RSI too high?
Context Therapeutics' current 9-Day RSI is 43.87. The Biotechnology industry median 9-Day RSI is 49.37. Context Therapeutics' value of 43.87 is 11.1% below this industry median. Based on the distribution chart, Context Therapeutics ranks #544 out of 1420 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Context Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Context Therapeutics' 9-Day RSI compare to INKT and XLO?
According to the Biotechnology industry distribution chart, Context Therapeutics ranks #544 out of 1420 companies for 9-Day RSI. This puts Context Therapeutics in the upper half of its industry. The industry median 9-Day RSI is 49.37. Context Therapeutics' value of 43.87 is 11.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 49.37, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Context Therapeutics's current 9-Day RSI of 43.87 is 11.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 49.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Context Therapeutics's current 9-Day RSI is 43.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Context Therapeutics stock overvalued right now?
Context Therapeutics (STU:6K9) has a current 9-Day RSI of 43.87. The current 9-Day RSI is 43.87 and 11.1% below the Biotechnology industry median of 49.37. Context Therapeutics' overall GF Score™ is 36/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Context Therapeutics (STU:6K9), the current 9-Day RSI is 43.87 as of Aug. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of various therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody (bsAb) that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
36GF Score
Get the complete analysis for STU:6K9
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:6K9 has been successfully added to your 
